Point Estimation: Odds Ratios, Hazard Ratios, Risk Differences, Precision Elizabeth S. Garrett Oncology Biostatistics March 20, 2002 Clinical.

Slides:



Advertisements
Similar presentations
Surviving Survival Analysis
Advertisements

Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.
Clinical 101: Clinical trial endpoints: Selection, analysis and interpretation Elizabeth Garrett-Mayer, PhD Hollings Cancer Center Medical University of.
Survival Analysis. Statistical methods for analyzing longitudinal data on the occurrence of events. Events may include death, injury, onset of illness,
Departments of Medicine and Biostatistics
Robertson JFR et al. J Clin Oncol 2009;27(27):
بسم الله الرحمن الرحیم. Generally,survival analysis is a collection of statistical procedures for data analysis for which the outcome variable of.
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
PH6415 Review Questions. 2 Question 1 A journal article reports a 95%CI for the relative risk (RR) of an event (treatment versus control as (0.55, 0.97).
Sample Size Determination Ziad Taib March 7, 2014.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 12: Multiple and Logistic Regression Marshall University.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Statistical Issues in Data Collection and Study Design For Community Programs and Research October 11, 2001 Elizabeth Garrett Division of Biostatistics.
Drug Treatment of Metastatic Breast Cancer
7 Regression & Correlation: Rates Basic Medical Statistics Course October 2010 W. Heemsbergen.
What do you think about a doctor who uses the wrong treatment, either wilfully or through ignorance, or who uses the right treatment wrongly (such as by.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Biostatistics Breakdown Common Statistical tests Special thanks to: Christyn Mullen, Pharm.D. Clinical Pharmacy Specialist John Peter Smith Hospital 1.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Estimation of Various Population Parameters Point Estimation and Confidence Intervals Dr. M. H. Rahbar Professor of Biostatistics Department of Epidemiology.
Confidence Intervals Elizabeth S. Garrett Oncology Biostatistics March 27, 2002 Clinical Trials in 20 Hours.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Evidence Based Medicine
Confidence Intervals Elizabeth Garrett-Mayer
Review of Chapters 1- 5 We review some important themes from the first 5 chapters 1.Introduction Statistics- Set of methods for collecting/analyzing data.
Assessing Survival: Cox Proportional Hazards Model
Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.
Competing Risks in Radiation Oncology Research Biostatistics Lecture June 17, 2010 Elizabeth Garrett-Mayer Amy Wahlquist.
Sampling and Confidence Interval Kenneth Kwan Ho Chui, PhD, MPH Department of Public Health and Community Medicine
HSRP 734: Advanced Statistical Methods July 17, 2008.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Statistical Review: Recursive Partitioning Identifies Patients at High and Low Risk for Ipsilateral Tumor Recurrence After Breast- Conserving Surgery and.
Sample Size August, 2007 Charles E. McCulloch Professor and Head, Division of Biostatistics Department of Epidemiology and Biostatistics.
Randomized Trial of Preoperative Chemoradiation Versus Surgery Alone in Patients with Locoregional Esophageal Carcinoma, Ursa et al. Statistical Methods:
Empirical Efficiency Maximization: Locally Efficient Covariate Adjustment in Randomized Experiments Daniel B. Rubin Joint work with Mark J. van der Laan.
Assessing Binary Outcomes: Logistic Regression Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
MBP1010 – Lecture 8: March 1, Odds Ratio/Relative Risk Logistic Regression Survival Analysis Reading: papers on OR and survival analysis (Resources)
Statistical Inference for more than two groups Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
1 Risk Assessment Tests Marina Kondratovich, Ph.D. OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel for Direct-to-Consumer (DTC) Genetic.
Medical Statistics as a science
Lecture 12: Cox Proportional Hazards Model
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
1 Follow the three R’s: Respect for self, Respect for others and Responsibility for all your actions.
Summarizing Risk Analysis Results To quantify the risk of an output variable, 3 properties must be estimated: A measure of central tendency (e.g. µ ) A.
Statistics for Neurosurgeons A David Mendelow Barbara A Gregson Newcastle upon Tyne England, UK.
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Logistic Regression. Linear regression – numerical response Logistic regression – binary categorical response eg. has the disease, or unaffected by the.
Descriptive Statistics Tabular and Graphical Displays –Frequency Distribution - List of intervals of values for a variable, and the number of occurrences.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
X Treatment population Control population 0 Examples: Drug vs. Placebo, Drugs vs. Surgery, New Tx vs. Standard Tx  Let X = decrease (–) in cholesterol.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
Direct method of standardization of indices. Average Values n Mean:  the average of the data  sensitive to outlying data n Median:  the middle of the.
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 13: Multiple, Logistic and Proportional Hazards Regression.
Statistical issues: Designing your trial for success ELIZABETH GARRETT-MAYER, PHD PROFESSOR OF BIOSTATISTICS HOLLINGS CANCER CENTER, MEDICAL UNIVERSITY.
Farletuzumab in platinum sensitive ovarian cancer with low CA125
Perez EA et al. SABCS 2009;Abstract 80.
Overview of Standard Phase II Design Issues
ASCO Recap Palak Desai, MD.
Basic Statistics Overview
Statistics 103 Monday, July 10, 2017.
NURS 790: Methods for Research and Evidence Based Practice
Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios
Presentation transcript:

Point Estimation: Odds Ratios, Hazard Ratios, Risk Differences, Precision Elizabeth S. Garrett Oncology Biostatistics March 20, 2002 Clinical Trials in 20 Hours

3/20/2002Clinical Trials in 20 Hours2 Point Estimation Definition: A “point estimate” is a one- number summary of data. If you had just one number to summarize the inference from your study….. Examples: –Dose finding trials: MTD (maximum tolerable dose) –Safety and Efficacy Trials: response rate, median survival –Comparative Trials: Odds ratio, hazard ratio

3/20/2002Clinical Trials in 20 Hours3 Types of Variables The point estimate you choose depends on the “nature” of the outcome of interest Continuous Variables –Examples: change in tumor volume or tumor diameter –Commonly used point estimates: mean, median Binary Variables –Examples: response, progression, > 50% reduction in tumor size –Commonly used point estimate: proportion, relative risk, odds ratio Time-to-Event (Survival) Variables –Examples: time to progression, time to death, time to relapse –Commonly used point estimates: median survival, k-year survival, hazard ratio Other types of variables: nominal categorical, ordinal categorical

3/20/2002Clinical Trials in 20 Hours4 Today Point Estimates commonly seen (and misunderstood) in clinical oncology –odds ratio –risk difference –hazard ratio/risk ratio

3/20/2002Clinical Trials in 20 Hours5 Point Estimates: Odds Ratios “Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer”, Potosky, Harlan, Kaplan, Johnson, Lynch. JCO, vol. 20 (5), March 2002, p Example: Is gender associated with use of standard adjuvant therapy (SAT) for patients with newly diagnosed stage III colon or stage II/III rectal cancer? –53% of men received SAT* –62% of women received SAT* How do we quantify the difference? * adjusted for other variables

3/20/2002Clinical Trials in 20 Hours6 Odds and Odds Ratios Odds = p/(1-p) The odds of a man receiving SAT is 0.53/( ) = The odds of a woman receiving SAT is 0.62/( ) = Odds Ratio = 1.63/1.13 = 1.44 Interpretation: “A woman is 1.44 times more likely to receive SAT than a man.”

3/20/2002Clinical Trials in 20 Hours7 Odds Ratio Odds Ratio for comparing two proportions OR > 1: increased risk of group 1 compared to 2 OR = 1: no difference in risk of group 1 compared to 2 OR < 1: lower risk (“protective”) in risk of group 1 compared to 2 In our example, –p 1 = proportion of women receiving SAT –p 2 = proportion of men receiving SAT

3/20/2002Clinical Trials in 20 Hours8 Odds Ratio from a 2x2 table

3/20/2002Clinical Trials in 20 Hours9

3/20/2002Clinical Trials in 20 Hours10 More on the Odds Ratio Ranges from 0 to infinity Tends to be skewed (i.e. not symmetric) –“protective” odds ratios range from 0 to 1 –“increased risk” odds ratios range from 1 to  Example: –“Women are at 1.44 times the risk/chance of men” –“Men are at 0.69 times the risk/chance of women”

3/20/2002Clinical Trials in 20 Hours11 More on the Odds Ratio Sometimes, we see the log odds ratio instead of the odds ratio. The log OR comparing women to men is log(1.44) = 0.36 The log OR comparing men to women is log(0.69) = log OR > 0: increased risk log OR = 0: no difference in risk log OR < 0: decreased risk

3/20/2002Clinical Trials in 20 Hours12 Related Measures of Risk Relative Risk: RR = p 1 /p 2 –RR = 0.62/0.53 = –Different way of describing a similar idea of risk. –Generally, interpretation “in words” is the similar: “Women are at 1.17 times as likely as men to receive SAT” –RR is appropriate in trials often. –But, RR is not appropriate in many settings (e.g. case-control studies) –Need to be clear about RR versus OR: p 1 = 0.50, p 2 = RR = 0.5/0.25 = 2 OR = (0.5/0.5)/(0.25/0.75) = 3 Same results, but OR and RR give quite different magnitude

3/20/2002Clinical Trials in 20 Hours13 Related Measures of Risk Risk Difference: p 1 - p 2 –Instead of comparing risk via a ratio, we compare risks via a difference. –In many CT’s, the goal is to increase response rate by a fixed percentage. –Example: the current success/response rate to a particular treatment is The goal for new therapy is a response rate of –If this goal is reached, then the “risk difference” will be 0.20.

3/20/2002Clinical Trials in 20 Hours14 Why do we so often see OR and not others? (1) Logistic regression: –Allows us to look at association between two variables, adjusted for other variables. –“Output” is a log odds ratio. –Example: In the gender ~ SAT example, the odds ratios were evaluated using logistic regression. In reality, the gender ~ SAT odds ratio is adjusted for age, race, year of dx, region, marital status,….. (2) Can be more globally applied. Design of study does not restrict usage.

3/20/2002Clinical Trials in 20 Hours15 Another Example “Randomized Controlled Trial of Single- Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients with Recurrent Ovarian Cancer Who Responded to First-line Platinum-Based Regimens”, Cantu, Parma, Rossi, Floriani, Bonazzi, Dell’Anna, Torri, Colombo. JCO, vol. 20 (5), March 2002, p Groups: paclitaxel (n = 47) versus CAP (n = 47) “14 patients in the CAP group and 8 patients in the paclitaxel group had complete responses p1 = 14/47 = 0.30; p2 = 8/47 = 0.17 OR = (0.30/0.70)/(0.17/0.83) = 2.1

3/20/2002Clinical Trials in 20 Hours16 Odds Ratio via 2x2 table “14 patients in the CAP group and 8 patients in the paclitaxel group had complete responses “Patients in the CAP group are twice as likely to have a CR as those in the paclitaxel group.” 2x2 Table approach: OR = ad/bc = (14*39)/(8*33) = 2.1

3/20/2002Clinical Trials in 20 Hours17 “Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients with Recurrent Ovarian Cancer Who Responded to First-line Platinum-Based Regimens”, Cantu, Parma, Rossi, Floriani, Bonazzi, Dell’Anna, Torri, Colombo. JCO, vol. 20 (5), March 2002, p Point Estimates: Hazard Ratios “What is the effect of CAP on overall survival as compared to paclitaxel?” –Median survival in CAP group was 34.7 months. –Median survival in paclitaxel group was 25.8 months. But, median survival doesn’t tell the whole story…..

3/20/2002Clinical Trials in 20 Hours18 Hazard Ratio Compares risk of event in two populations or samples Ratio of risk in group 1 to risk in group 2 First things first….. –Kaplan-Meier Curves (product- limit estimate) –Makes a “picture” of survival

3/20/2002Clinical Trials in 20 Hours19 Hazard Ratios Assumption: “Proportional hazards” The risk does not depend on time. That is, “risk is constant over time” But that is still vague….. Hypothetical Example: Assume hazard ratio is 2. –Patients in standard therapy group are at twice the risk of death as those in new drug, at any given point in time. Hazard function= P(die at time t | survived to time t)

3/20/2002Clinical Trials in 20 Hours20 Hazard Ratios Hazard Ratio = hazard function for Std hazard function for New Makes the assumption that this ratio is constant over time.

3/20/2002Clinical Trials in 20 Hours21 Hazard Ratios Hazard Ratio = hazard function for Pac hazard function for CAP Makes the assumption that this ratio is constant over time.  HR = 2

3/20/2002Clinical Trials in 20 Hours22 Hazard Ratios Hazard Ratio = hazard function for Pac hazard function for CAP Makes the assumption that this ratio is constant over time. HR = 2  

3/20/2002Clinical Trials in 20 Hours23 Interpretation Again For any fixed point in time, individuals in the standard therapy group are at twice the risk of death as the new drug group. HR = 2  

3/20/2002Clinical Trials in 20 Hours24 Hazard ratio is not always valid …. Hazard Ratio =.71

3/20/2002Clinical Trials in 20 Hours25 CAP vs. Paclitaxel Hazard Ratio for Progression Free Survival: 0.60 for CAP vs. Paclitaxel

3/20/2002Clinical Trials in 20 Hours26 CAP vs. Paclitaxel Hazard Ratio for Overall Survival: 0.58 for CAP vs. Paclitaxel

3/20/2002Clinical Trials in 20 Hours27 Introduction to Precision Issues PrecisionVariability Two kinds of variability we tend to deal with –variation in the population: how much do individuals tend to differ from one another? –variance of statistics: how certain are we of our estimate of the odds ratio? There might be great variability in the population, but with a large sample size, we can have very good precision for a sample statistic.

3/20/2002Clinical Trials in 20 Hours28 Standard Deviation Standard deviation measures how much variability there is in a variable across individuals in the population CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin’s Disease: Associations with Presenting Features and Clinical Outcome, Rassidakis, Mederios, Viviani, et al. JCO, March 1, 2002, v. 20(5), p

3/20/2002Clinical Trials in 20 Hours29 Standard Deviation Mean: Standard Deviation:

3/20/2002Clinical Trials in 20 Hours30 Other measures of precision for continuous variables Range: the smallest and largest values of x IQR (interquartile range): 25% percentile and 75% percentile of the data 25%-tile 75%-tile

3/20/2002Clinical Trials in 20 Hours31 Precision Standardized Uptake Value in 2-[18F] Fluro-2-Deoxy-D- Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy, Allal, Dulgerov, Allaoua, Haeggeli, Ghazi, Lehmann, Slosman, JCO, March 1, 2002, v. 20(5), p Event = treatment failure

3/20/2002Clinical Trials in 20 Hours32 Next time: Confidence Intervals Measuring precision of statistics Central limit theorem Confidence intervals for –means –proportions –odds ratios –etc…..